Data Sheet (Cat.No.T6826)

TargetMol

Emricasan

Chemical Properties



CAS No. : 254750-02-2

Formula: C26H27F4N3O7

Molecular Weight: 569.5

Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Actual storage temperature shall be subject to the COA.

Biological Description

Description	Emricasan (IDN-6556) is a pan-caspase inhibitor with irreversible properties. Emricasan has anti-inflammatory and anti-apoptotic activity and can be used in the treatment of infections and liver failure, etc. Emricasan also inhibits Zika virus infections.
Targets(IC50)	Anti-infection,Caspase,Influenza Virus
In vitro	**METHODS**: Primary rat cirrhotic hepatocytes were treated with Emricasan (50 μM) for 24 h, and mRNA expression levels were measured. **RESULTS**: Emricasan directly improved the expression of hepatocyte-specific markers. [1] **METHODS**: Human cervical cancer cells HeLa were pretreated with Emricasan (10 μM) for 1 h, then treated with vincristine (20 nM) for 44 h. Cell death was detected by Flow Cytometry. **RESULTS**: Emricasan eliminated 95% of vincristine-mediated cell death. [2]
In vivo	**METHODS**: To study the effects on chronic liver disease, Emricasan (10 mg/kg, 0.9% dimethylcarboxycellulose) was administered orally once daily for seven days to rats with advanced cirrhosis due to chronic CCl_4 administration. **RESULTS**: Emricasan ameliorated hepatic sinusoidal microvascular dysfunction in cirrhotic patients, resulting in significant improvement in fibrosis, portal hypertension and liver function. [1] **METHODS**: To investigate the effects on cirrhosis, Emricasan (10 mg/kg) was administered intraperitoneally once daily for 10-20 days to C57BL/6 mice with secondary biliary cirrhosis induced by bile duct ligation (BDL). **RESULTS**: Emricasan treatment improved survival and portal hypertension (PHT) in a mouse model of long-term BDL. [3]
Cell Research	Astrocytes are mock-infected, treated with DMSO or treated with 2 μM niclosamide, 92 μM PHA-690509, 9 μM emricasan, or a combination of 92 μM PHA-690509 and 9 μM emricasan for 1 h before infection with PRVABC59 (MOI = 0.5). Cells are fixed 24 h after infection and stained for ZIKVE and nuclei.(Only for Reference)

Solubility Information

Solubility	H2O: < 1 mg/mL (insoluble or slightly soluble), DMSO: 257.5 mg/mL (452.15 mM),Sonication is recommended.

Solubility	Ethanol: 93 mg/mL (163.3 mM),Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)
In vivo Formulation	10% DMSO+40% PEG300+5% Tween 80+45% Saline: 5 mg/mL (8.78 mM),Solution. *Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.*

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	1.7559 mL	8.7796 mL	17.5593 mL
5 mM	0.3512 mL	1.7559 mL	3.5119 mL
10 mM	0.1756 mL	0.878 mL	1.7559 mL
50 mM	0.0351 mL	0.1756 mL	0.3512 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

Gracia-Sancho J, et al. Emricasan Ameliorates Portal Hypertension and Liver Fibrosis in Cirrhotic Rats Through a Hepatocyte-Mediated Paracrine Mechanism. Hepatol Commun. 2019 Apr 22;3(7):987-1000.
Tang Q, Li W, Zheng X, et al. MELK is an oncogenic kinase essential for metastasis, mitotic progression, and programmed death in lung carcinoma. Signal Transduction and Targeted Therapy. 2020, 5(1): 1-12.
Bosc E, et al. Genuine selective caspase-2 inhibition with new irreversible small peptidomimetics. Cell Death Dis. 2022 Nov 15;13(11):959.
Tang Q, Ren L, Liu J, et al. Withaferin A triggers G2/M arrest and intrinsic apoptosis in glioblastoma cells via ATF4-ATF3-CHOP axis. Cell proliferation. 2019: e12706
Eguchi A, et al. Emricasan, a pan-caspase inhibitor, improves survival and portal hypertension in a murine model of common bile-duct ligation. J Mol Med (Berl). 2018 Jun;96(6):575-583.
Zhou R, You Y, Zha Z, et al.Biotin decorated celastrol-loaded ZIF-8 nano-drug delivery system targeted epithelial ovarian cancer therapy.Biomedicine & Pharmacotherapy.2023, 167: 115573.
Li J, Han X, Sun M, et al.Caspase-9 inhibition triggers Hsp90-based chemotherapy-mediated tumor intrinsic innate sensing and enhances antitumor immunity.Journal for Immunotherapy of Cancer.2023, 11(12).
Tang Q, Ren L, Liu J, et al. Withaferin A triggers G2/M arrest and intrinsic apoptosis in glioblastoma cells via ATF4-ATF3-CHOP axis[J]. Cell proliferation. 2019: e12706.
Chen J, Liu Y, You Y, et al.Biotin-decorated celastrol-loaded ZIF-8 nanoparticles induce ferroptosis for colorectal cancer therapy.Materials & Design.2024: 112814.